| Treatments | |||||
---|---|---|---|---|---|---|
Fatty Acid Measurement1 | CO | FO | KO | MO | SO | TO |
Gonadal Fat Pad | Â | Â | Â | Â | Â | Â |
n-3 PUFA | 1.3 ± 0.2c | 81.7 ± 6.8a | 21.5 ± 2.6b | 21.6 ± 2.0b | 9.5 ± 2.8bc | 13.5 ± 2.4bc |
ALA (18:3n-3) | 1.3 ± 0.2b | 80.9 ± 6.6a | 3.1 ± 0.4b | 5.0 ± 0.4b | 1.1 ± 0.2b | 2.0 ± 0.4b |
EPA (20:5n-3) | ND | 0.7 ± 0.2c | 9.7 ± 1.3a | 5.6 ± 0.9b | 4.2 ± 1.4bc | 1.9 ± 0.4bc |
DHA (22:6n-3) | ND | 0.07 ± 0.02c | 8.7 ± 1.2ab | 10.9 ± 1.0a | 4.2 ± 1.2bc | 9.7 ± 2.0a |
n-6 PUFA | 107.9 ± 14.1a | 59.8 ± 5.8b | 17.0 ± 2.0c | 21.0 ± 1.8c | 8.0 ± 1.4c | 11.6 ± 2.2c |
LA (18:2n-6) | 106.5 ± 13.9a | 59.4 ± 5.6b | 15.5 ± 1.9c | 19.5 ± 1.7c | 6.5 ± 1.3c | 8.5 ± 1.6c |
ARA (20:4n-6) | 1.4 ± 0.2b | 0.5 ± 0.1b | 1.6 ± 0.2b | 1.5 ± 0.1b | 1.4 ± 0.3b | 3.1 ± 0.7a |
Retroperitoneal Fat Pad | Â | Â | Â | Â | Â | Â |
n-3 PUFA | 2.9 ± 0.2c | 149.4 ± 15.1a | 45.7 ± 6.9b | 37.9 ± 5.1b | 20.4 ± 4.3bc | 23.1 ± 3.6bc |
ALA (18:3n-3) | 2.9 ± 0.2b | 148.4 ± 15.1a | 5.0 ± 0.6b | 8.0 ± 0.7b | 2.7 ± 0.3b | 2.8 ± 0.6b |
EPA (20:5n-3) | ND | 1.0 ± 0.2c | 19.9 ± 3.1a | 10.8 ± 1.6b | 10.5 ± 2.3b | 3.2 ± 0.7bc |
DHA (22:6n-3) | ND | ND | 20.7 ± 3.9a | 23.3 ± 2.1a | 9.4 ± 1.9b | 17.0 ± 2.8ab |
n-6 PUFA | 211.3 ± 25.4a | 97.7 ± 10.3b | 34.4 ± 4.9c | 33.6 ± 5.0c | 14.8 ± 2.8c | 13.9 ± 1.8c |
LA (18:2n-6) | 208.9 ± 25.2a | 97.2 ± 10.3b | 32.1 ± 4.9c | 34.4 ± 3.4c | 14.6 ± 2.5c | 11.4 ± 1.7c |
ARA (20:4n-6) | 2.4 ± 0.3ab | 0.5 ± 0.1c | 2.3 ± 0.3ab | 2.9 ± 0.2a | 1.8 ± 0.2b | 2.5 ± 0.2ab |